ATP12A and gastric cancer: In addition, a systematic review found that in 20 of 21 meta-analyses, the use of proton pump inhibitors (PPIs) was consistently associated with an increased risk of gastric cancer, with reported relative risks ranging from 1.3 to 2.9.